Vasopressin V2 Receptor Antagonist Drug Class List
✉ Email this page to a colleague
Drugs in Drug Class: Vasopressin V2 Receptor Antagonist
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apotex | TOLVAPTAN | tolvaptan | TABLET;ORAL | 207605-002 | Sep 6, 2022 | AB | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
| Hetero Labs Ltd V | TOLVAPTAN | tolvaptan | TABLET;ORAL | 205646-001 | Jul 16, 2021 | AB | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
| Apotex | TOLVAPTAN | tolvaptan | TABLET;ORAL | 207605-001 | May 19, 2020 | AB | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
| Endo Operations | TOLVAPTAN | tolvaptan | TABLET;ORAL | 206119-001 | Feb 15, 2022 | AB | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
| Alkem Labs Ltd | TOLVAPTAN | tolvaptan | TABLET;ORAL | 211891-003 | Sep 6, 2022 | AB | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
| Endo Operations | TOLVAPTAN | tolvaptan | TABLET;ORAL | 206119-002 | Feb 15, 2022 | AB | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
| Alkem Labs Ltd | TOLVAPTAN | tolvaptan | TABLET;ORAL | 211891-001 | May 19, 2020 | AB | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
